Newsfeeds Archive - Spark Newswire

1 minute read

CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst

February 13, 3:05 PM

Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800 million.

CBAY

6 minute read

Intercept Announces New Phase 2 Data Showing Significant Impact Of OCA-Bezafibrate Combination On Normalization Of Multiple Key Biomarkers Of PBC-Induced Liver Damage At AASLD The Liver Meeting 2023

By Benzinga Newsdesk

November 13, 9:33 AM

Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5

ICPT

5 minute read

Intercept Announces New Findings From Long-term Extension Of Landmark POISE Trial In PBC Showing Importance Of Biomarkers Beyond ALP At AASLD The Liver Meeting 2023

By Benzinga Newsdesk

November 10, 9:02 AM

New analysis demonstrates the impact of OCA on achievement of GGT <3.2×ULN and ALP <1.5×ULNFindings suggest that OCA has the potential to reduce the liver biomarker GGT, in addition to well-known effects

ICPT

1 minute read

Alfasigma S.p.A. Announces Expiration Of Hart-Scott-Rodino Waiting Period In Connection With Pending Acquisition Of Intercept Pharmaceuticals, Inc.

By Benzinga Newsdesk

October 26, 9:09 AM

Alfasigma S.p.A. ("Alfasigma") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") with respect to Alfasigma's proposed acquisition of Intercept

ICPT

2 minute read

Top 5 Health Care Stocks That Should Keep You Up At Night

By Lisa Levin

October 26, 8:49 AM

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

GPCR

3 minute read

EMA’s Human Medicines Committee Has Started A Review Of The Medicine Ocaliva; Study 747-302 Failed To Show That Ocaliva Was More Effective Than Placebo, Additionally, Side Effects, Including Serious Ones, Occurred More Frequently In Patients

By Benzinga Newsdesk

October 13, 3:57 PM

https://www.ema.europa.eu/en/documents/referral/ocaliva-article-20-procedure-review-ocaliva-started_en.pdf Review of Ocaliva started EMA's human medicines committee (CHMP) has started a review of the medicine

ICPT